Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 5/20 | 0.53 |
| ▸ | TRPC4 | Q9UBN4 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TRPC1 | P48995 | 1/20 | 0.49 |
| ▸ | PDE5A | O76074 | 4/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16028059 | 0.90 | TRPC5 (0.54) | TRPC5TRPC4KCNH2TP53TRPC1 | |
| SCHEMBL18834631 | 0.89 | TRPC5 (0.53) | TRPC5TRPC4KCNH2TP53TRPC1 | |
| SCHEMBL18834595 | 0.89 | TRPC5 (0.65) | TRPC5TRPC4KCNH2TP53TRPC1 | |
| SCHEMBL16028540 | 0.86 | TRPC5 (0.62) | TRPC5TRPC4KCNH2TP53TRPC1 | |
| SCHEMBL16076262 | 0.85 | TRPC5 (0.52) | TRPC5TRPC4KCNH2TP53TRPC1 | |
| SCHEMBL16028570 | 0.85 | TRPC5 (0.59) | TRPC5TRPC4KCNH2TP53TRPC1 | |
| SCHEMBL16028473 | 0.85 | TRPC5 (0.68) | TRPC5TRPC4KCNH2TP53TRPC1 | |
| SCHEMBL16028388 | 0.84 | TRPC5 (0.57) | TRPC5TRPC4KCNH2TP53TRPC1 | |
| SCHEMBL16028289 | 0.84 | TRPC5 (0.57) | TRPC5TRPC4KCNH2TP53TRPC1 | |
| SCHEMBL16364001 | 0.84 | ALDH1A1 (0.55) | TRPC5TRPC4KCNH2TP53TRPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970303-B9 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275071-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | TRPC5 1/4885TRPC4 3/4885KCNH2 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.